These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 34193440)

  • 1. A Humanized Animal Model Predicts Clonal Evolution and Therapeutic Vulnerabilities in Myeloproliferative Neoplasms.
    Celik H; Krug E; Zhang CR; Han W; Issa N; Koh WK; Bjeije H; Kukhar O; Allen M; Li T; Fisher DAC; Fowles JS; Wong TN; Stubbs MC; Koblish HK; Oh ST; Challen GA
    Cancer Discov; 2021 Dec; 11(12):3126-3141. PubMed ID: 34193440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What are the molecular mechanisms driving the switch from MPNs to leukemia?
    Wang X; Hoffman R
    Best Pract Res Clin Haematol; 2021 Mar; 34(1):101254. PubMed ID: 33762108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accelerated Phase of Myeloproliferative Neoplasms.
    Shahin OA; Chifotides HT; Bose P; Masarova L; Verstovsek S
    Acta Haematol; 2021; 144(5):484-499. PubMed ID: 33882481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells.
    Saenz DT; Fiskus W; Manshouri T; Rajapakshe K; Krieger S; Sun B; Mill CP; DiNardo C; Pemmaraju N; Kadia T; Parmar S; Sharma S; Coarfa C; Qiu P; Verstovsek S; Bhalla KN
    Leukemia; 2017 Mar; 31(3):678-687. PubMed ID: 27677740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ratio of stemness to interferon signalling as a biomarker and therapeutic target of myeloproliferative neoplasm progression to acute myeloid leukaemia.
    de Castro FA; Mehdipour P; Chakravarthy A; Ettayebi I; Loo Yau H; Medina TS; Marhon SA; de Almeida FC; Bianco TM; Arruda AGF; Devlin R; de Figueiredo-Pontes LL; Chahud F; da Costa Cacemiro M; Minden MD; Gupta V; De Carvalho DD
    Br J Haematol; 2024 Jan; 204(1):206-220. PubMed ID: 37726227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leukemic Transformation of Myeloproliferative Neoplasms: Therapeutic and Genomic Considerations.
    Li B; Mascarenhas JO; Rampal RK
    Curr Hematol Malig Rep; 2018 Dec; 13(6):588-595. PubMed ID: 30353413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms.
    Rampal R; Ahn J; Abdel-Wahab O; Nahas M; Wang K; Lipson D; Otto GA; Yelensky R; Hricik T; McKenney AS; Chiosis G; Chung YR; Pandey S; van den Brink MR; Armstrong SA; Dogan A; Intlekofer A; Manshouri T; Park CY; Verstovsek S; Rapaport F; Stephens PJ; Miller VA; Levine RL
    Proc Natl Acad Sci U S A; 2014 Dec; 111(50):E5401-10. PubMed ID: 25516983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.
    Abdel-Wahab O; Manshouri T; Patel J; Harris K; Yao J; Hedvat C; Heguy A; Bueso-Ramos C; Kantarjian H; Levine RL; Verstovsek S
    Cancer Res; 2010 Jan; 70(2):447-52. PubMed ID: 20068184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LKB1/
    Marinaccio C; Suraneni P; Celik H; Volk A; Wen QJ; Ling T; Bulic M; Lasho T; Koche RP; Famulare CA; Farnoud N; Stein B; Schieber M; Gurbuxani S; Root DE; Younger ST; Hoffman R; Gangat N; Ntziachristos P; Chandel NS; Levine RL; Rampal RK; Challen GA; Tefferi A; Crispino JD
    Cancer Discov; 2021 Jun; 11(6):1398-1410. PubMed ID: 33579786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia.
    Benton CB; Boddu PC; DiNardo CD; Bose P; Wang F; Assi R; Pemmaraju N; Kc D; Pierce S; Patel K; Konopleva M; Ravandi F; Garcia-Manero G; Kadia TM; Cortes J; Kantarjian HM; Andreeff M; Verstovsek S
    Cancer; 2019 Jun; 125(11):1855-1866. PubMed ID: 30811597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic Vulnerabilities and Epigenetic Dysregulation in Myeloproliferative Neoplasms.
    Sharma V; Wright KL; Epling-Burnette PK; Reuther GW
    Front Immunol; 2020; 11():604142. PubMed ID: 33329600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Pathogenesis of Myeloproliferative Neoplasms.
    Rolles B; Mullally A
    Curr Hematol Malig Rep; 2022 Dec; 17(6):319-329. PubMed ID: 36336766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Molecular Insights into Leukemic Evolution of Myeloproliferative Neoplasms: A Single Cell Perspective.
    Rontauroli S; Carretta C; Parenti S; Bertesi M; Manfredini R
    Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogenesis and management of acute myeloid leukemia that has evolved from a myeloproliferative neoplasm.
    Rampal R; Mascarenhas J
    Curr Opin Hematol; 2014 Mar; 21(2):65-71. PubMed ID: 24366192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-existence of mutations in myeloproliferative neoplasms and their clinical significance: a prognostic approach.
    Homaei Hadad E; Pezeshki SMS; Shahrabi S; Saki Malehi A; Saki N
    Expert Rev Hematol; 2020 Nov; 13(11):1289-1301. PubMed ID: 32886563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current clinical strategies and emergent treatment landscapes in leukemic transformation of Philadelphia-negative myeloproliferative neoplasms.
    Abruzzese E; Niscola P
    Expert Rev Hematol; 2020 Dec; 13(12):1349-1359. PubMed ID: 33226274
    [No Abstract]   [Full Text] [Related]  

  • 17. Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML.
    Saenz DT; Fiskus W; Manshouri T; Mill CP; Qian Y; Raina K; Rajapakshe K; Coarfa C; Soldi R; Bose P; Borthakur G; Kadia TM; Khoury JD; Masarova L; Nowak AJ; Sun B; Saenz DN; Kornblau SM; Horrigan S; Sharma S; Qiu P; Crews CM; Verstovsek S; Bhalla KN
    Leukemia; 2019 Jun; 33(6):1373-1386. PubMed ID: 30575820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Megakaryocytes in Myeloproliferative Neoplasms Have Unique Somatic Mutations.
    Guo BB; Allcock RJ; Mirzai B; Malherbe JA; Choudry FA; Frontini M; Chuah H; Liang J; Kavanagh SE; Howman R; Ouwehand WH; Fuller KA; Erber WN
    Am J Pathol; 2017 Jul; 187(7):1512-1522. PubMed ID: 28502479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms.
    Fisher DAC; Fowles JS; Zhou A; Oh ST
    Front Immunol; 2021; 12():683401. PubMed ID: 34140953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms.
    Venton G; Courtier F; Charbonnier A; D'incan E; Saillard C; Mohty B; Mozziconacci MJ; Birnbaum D; Murati A; Vey N; Rey J
    Am J Hematol; 2018 Mar; 93(3):330-338. PubMed ID: 29148089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.